Thomas Joseph Weber
Professor of Medicine
Osteoporosis, with current studies that focus on advances in diagnosis and natural history of male and postmenopausal osteoporosis. The study on male osteoporosis include a collaborative study with outside investigators is examining the utility of lateral spine bone densitometry in identifying men with osteoporosis and low trauma fractures.
Hypophosphatemic disorders, including X-link hypophosphatemic rickets and tumor-induced osteomalacia. My ongoing research study, in collaboration with Dr. L Darryl Quarles at the University of Kansas, seeks to further confirm and extend our understanding of the role of FGF-23 in human disorders of phosphate homeostasis, including patients with chronic kidney disease. Pending studies include primary and sub-investigator directed Phase 1 / 2 first in human studies examining the effects of a monoclonal antibody and enzyme replacement therapy for X-linked hypophosphatemic rickets and hypophosphatasia, respectively.
Hypophosphatemic disorders, including X-link hypophosphatemic rickets and tumor-induced osteomalacia. My ongoing research study, in collaboration with Dr. L Darryl Quarles at the University of Kansas, seeks to further confirm and extend our understanding of the role of FGF-23 in human disorders of phosphate homeostasis, including patients with chronic kidney disease. Pending studies include primary and sub-investigator directed Phase 1 / 2 first in human studies examining the effects of a monoclonal antibody and enzyme replacement therapy for X-linked hypophosphatemic rickets and hypophosphatasia, respectively.
Current Appointments & Affiliations
- Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2021
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2016
Contact Information
- 303 Baker House, Durham, NC 27710
- Duke Box 3470, Durham, NC 27710
-
thomas.weber2@duke.edu
(919) 681-2055
- Background
-
Education, Training, & Certifications
- Fellow in Endocrinology, Medicine, Duke University 1993 - 1997
- Medical Resident, Medicine, Yale University 1989 - 1992
- M.D., The University of Chicago 1989
-
Previous Appointments & Affiliations
- Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2020
- Associate Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2010 - 2020
- Assistant Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2009 - 2010
- Assistant Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 2001 - 2009
- Associate in the Department of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 1997 - 2001
- Instructor, Temporary in the Department of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition, Medicine 1997
-
Academic Positions Outside Duke
- Instructor, Yale University. 1992 - 1993
- Research
-
Selected Grants
- X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP) UX023-CL401 awarded by Ultragenyx Pharmaceutical 2018 - 2028
- Endocrinology and Metabolism Training Program (T32) awarded by National Institutes of Health 2019 - 2024
- Clinical indicators for early bone loss in Common Variable Immunodeficiency awarded by Immune Deficiency Foundation 2019 - 2020
- A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) awarded by Ultragenyx Pharmaceutical 2015 - 2019
- A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects with X-Linked Hypophosphatemia (XLH) awarded by Ultragenyx Pharmaceutical 2015 - 2019
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of KRN23 in Adult Patients with X-linked Hypophosphatemia (XLH)¿ awarded by Ultragenyx Pharmaceutical 2015 - 2019
- An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults with X-Linked Hypophosphatemia (XLH) awarded by Ultragenyx Pharmaceutical 2015 - 2017
- HIV and Asthma in the Post- ART Era awarded by National Institutes of Health 2014 - 2016
- Clinically vs. pathologically negative lymph nodes in patients with papillary thyroid cancer: survival, radioactive iodine therapy and lymphadenectomy patterns of use awarded by Endocrine Fellows Foundation 2015 - 2016
-
External Relationships
- AgNovos Healthcare
- Bone Health and Osteoporosis Foundation
- Carolina Society of Endocrinologists
- Food and Drug Administration
- HMP Global
- Open Health Group
- The Endocrine Society
- Ultragenyx
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Weber, Thomas J., Erik A. Imel, Thomas O. Carpenter, Munro Peacock, Anthony A. Portale, Joel Hetzer, J Lawrence Merritt, and Karl Insogna. “Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.” J Clin Endocrinol Metab 108, no. 1 (December 17, 2022): 155–65. https://doi.org/10.1210/clinem/dgac518.Full Text Link to Item
-
Bergmann, Felix, Peter Matzneller, Maria Weber, Lusine Yeghiazaryan, Thorsten Fuereder, Thomas Weber, and Markus Zeitlinger. “Perception of clinical research among patients and healthy volunteers of clinical trials.” Eur J Clin Pharmacol 78, no. 10 (October 2022): 1647–55. https://doi.org/10.1007/s00228-022-03366-3.Full Text Link to Item
-
Brandi, Maria Luisa, Suzanne Jan de Beur, Karine Briot, Thomas Carpenter, Hae Il Cheong, Martine Cohen-Solal, Rachel K. Crowley, et al. “Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.” Calcif Tissue Int 111, no. 4 (October 2022): 409–18. https://doi.org/10.1007/s00223-022-01006-7.Full Text Link to Item
-
Jan de Beur, Suzanne M., Paul D. Miller, Thomas J. Weber, Munro Peacock, Karl Insogna, Rajiv Kumar, Frank Rauch, et al. “Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing.” J Bone Miner Res 36, no. 12 (December 2021): 2455–56. https://doi.org/10.1002/jbmr.4317.Full Text Link to Item
-
Briot, Karine, Anthony A. Portale, Maria Luisa Brandi, Thomas O. Carpenter, Hae Ii Cheong, Martine Cohen-Solal, Rachel K. Crowley, et al. “Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.” Rmd Open 7, no. 3 (September 2021). https://doi.org/10.1136/rmdopen-2021-001714.Full Text Link to Item
-
Dahir, Kathryn, María Belén Zanchetta, Irinel Stanciu, Cemre Robinson, Janet Y. Lee, Ruban Dhaliwal, Julia Charles, et al. “Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.” J Endocr Soc 5, no. 9 (September 1, 2021): bvab099. https://doi.org/10.1210/jendso/bvab099.Full Text Link to Item
-
Jan de Beur, Suzanne M., Paul D. Miller, Thomas J. Weber, Munro Peacock, Karl Insogna, Rajiv Kumar, Frank Rauch, et al. “Burosumab for the Treatment of Tumor-Induced Osteomalacia.” J Bone Miner Res 36, no. 4 (April 2021): 627–35. https://doi.org/10.1002/jbmr.4233.Full Text Link to Item
-
Wolf, Myles, Janet Rubin, Maureen Achebe, Michael J. Econs, Munro Peacock, Erik A. Imel, Lars L. Thomsen, et al. “Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.” Jama 323, no. 5 (February 4, 2020): 432–43. https://doi.org/10.1001/jama.2019.22450.Full Text Link to Item
-
Portale, Anthony A., Thomas O. Carpenter, Maria Luisa Brandi, Karine Briot, Hae Ii Cheong, Martine Cohen-Solal, Rachel Crowley, et al. “Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.” Calcif Tissue Int 105, no. 3 (September 2019): 271–84. https://doi.org/10.1007/s00223-019-00568-3.Full Text Link to Item
-
Kim-Chang, Julie J., Lorena Wilson, Cliburn Chan, Bernard Fischer, Guglielmo Venturi, Maureen M. Goodenow, Grace Aldrovandi, Thomas J. Weber, John W. Sleasman, and John W. Adolescent Medicine Trials Network for HIV/AIDS Interventions. “Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.” Aids Res Hum Retroviruses 35, no. 8 (August 2019): 746–54. https://doi.org/10.1089/AID.2018.0270.Full Text Link to Item
-
Insogna, Karl L., Karine Briot, Erik A. Imel, Peter Kamenický, Mary D. Ruppe, Anthony A. Portale, Thomas Weber, et al. “A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.” J Bone Miner Res 33, no. 8 (August 2018): 1383–93. https://doi.org/10.1002/jbmr.3475.Full Text Link to Item
-
Weber, Thomas J., James Koh, Samantha M. Thomas, Joyce A. Hogue, Randall P. Scheri, Sanziana A. Roman, and Julie A. Sosa. “Impaired calcium sensing distinguishes primary hyperparathyroidism (PHPT) patients with low bone mineral density.” Metabolism 74 (September 2017): 22–31. https://doi.org/10.1016/j.metabol.2017.06.004.Full Text Link to Item
-
Mori, Mari, Stephanie L. DeArmey, Thomas J. Weber, and Priya S. Kishnani. “Case series: Odontohypophosphatasia or missed diagnosis of childhood/adult-onset hypophosphatasia? - Call for a long-term follow-up of premature loss of primary teeth.” Bone Rep 5 (December 2016): 228–32. https://doi.org/10.1016/j.bonr.2016.08.004.Full Text Link to Item
-
Ruppe, Mary D., Xiaoping Zhang, Erik A. Imel, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, et al. “Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia.” Bone Rep 5 (December 2016): 158–62. https://doi.org/10.1016/j.bonr.2016.05.004.Full Text Link to Item
-
Weber, Thomas J., Eileen K. Sawyer, Scott Moseley, Tatjana Odrljin, and Priya S. Kishnani. “Burden of disease in adult patients with hypophosphatasia: Results from two patient-reported surveys.” Metabolism 65, no. 10 (October 2016): 1522–30. https://doi.org/10.1016/j.metabol.2016.07.006.Full Text Link to Item
-
Weber, Thomas J. “Battle of the sex steroids in the male skeleton: and the winner is...” J Clin Invest 126, no. 3 (March 1, 2016): 829–32. https://doi.org/10.1172/JCI85006.Full Text Link to Item
-
Zhang, Xiaoping, Erik A. Imel, Mary D. Ruppe, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, et al. “Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia.” J Clin Pharmacol 56, no. 2 (February 2016): 176–85. https://doi.org/10.1002/jcph.570.Full Text Link to Item
-
Weber, Thomas J., Eileen K. Sawyer, Scott Moseley, and Priya S. Kishnani. “Diminished Health-Related Quality of Life As Measured By the Short Form-10 in Children with Hypophosphatasia.” Arthritis & Rheumatology 67 (October 1, 2015).Link to Item
-
Imel, Erik A., Xiaoping Zhang, Mary D. Ruppe, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, et al. “Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.” J Clin Endocrinol Metab 100, no. 7 (July 2015): 2565–73. https://doi.org/10.1210/jc.2015-1551.Full Text Link to Item
-
Carpenter, Thomas O., Erik A. Imel, Mary D. Ruppe, Thomas J. Weber, Mark A. Klausner, Margaret M. Wooddell, Tetsuyoshi Kawakami, et al. “Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.” J Clin Invest 124, no. 4 (April 2014): 1587–97. https://doi.org/10.1172/JCI72829.Full Text Link to Item
-
Lee, Richard H., Thomas Weber, and Cathleen Colón-Emeric. “Comparison of cost-effectiveness of vitamin D screening with that of universal supplementation in preventing falls in community-dwelling older adults.” J Am Geriatr Soc 61, no. 5 (May 2013): 707–14. https://doi.org/10.1111/jgs.12213.Full Text Link to Item
-
Pham, Annalise N., Santanu K. Datta, Thomas J. Weber, Louise C. Walter, and Cathleen S. Colón-Emeric. “Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy.” J Am Geriatr Soc 59, no. 9 (September 2011): 1642–49. https://doi.org/10.1111/j.1532-5415.2011.03571.x.Full Text Link to Item
-
Solimeo, Samantha L., Thomas J. Weber, and Deborah T. Gold. “Older men's explanatory model for osteoporosis.” Gerontologist 51, no. 4 (August 2011): 530–39. https://doi.org/10.1093/geront/gnq123.Full Text Link to Item
-
Lakey, Wanda C., Susan Spratt, Emily N. Vinson, Diane Gesty-Palmer, Thomas Weber, and Scott Palmer. “Osteoporosis in lung transplant candidates compared to matched healthy controls.” Clin Transplant 25, no. 3 (2011): 426–35. https://doi.org/10.1111/j.1399-0012.2010.01263.x.Full Text Link to Item
-
Lee, Richard, and Thomas J. Weber. “Disorders of phosphorus homeostasis.” Curr Opin Endocrinol Diabetes Obes 17, no. 6 (December 2010): 561–67. https://doi.org/10.1097/MED.0b013e32834041d4.Full Text Link to Item
-
Banugaria, Suhrad G., Stephanie L. Austin, Anne Boney, Thomas J. Weber, and Priya S. Kishnani. “Hypovitaminosis D in glycogen storage disease type I.” Mol Genet Metab 99, no. 4 (April 2010): 434–37. https://doi.org/10.1016/j.ymgme.2009.12.012.Full Text Link to Item
-
Nair, Lekshmi T., Leslie Dodd, and Thomas J. Weber. “Following the forgotten phosphorus.” Am J Med 122, no. 12 (December 2009): 1093–95. https://doi.org/10.1016/j.amjmed.2009.07.006.Full Text Link to Item
-
Pham, A. N., C. S. Colón-Emeric, and T. J. Weber. “Osteoporosis in older women.” Clinical Geriatrics 17, no. 10 (October 1, 2009): 20–28.
-
Matsumoto, Alvin M., Peter J. Snyder, Shalender Bhasin, Kathryn Martin, Thomas Weber, Stephen Winters, Daniel Spratt, Jim Brentzel, and Louis O’Dea. “Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism.” Fertil Steril 92, no. 3 (September 2009): 979–90. https://doi.org/10.1016/j.fertnstert.2008.07.1742.Full Text Link to Item
-
Coursey, Courtney, Thomas Weber, Leslie Dodd, and Salutario Martinez. “Fibrogenesis imperfecta ossium: MR imaging of the axial and appendicular skeleton and correlation with a unique radiographic appearance.” Skeletal Radiol 36, no. 11 (November 2007): 1077–84. https://doi.org/10.1007/s00256-007-0334-2.Full Text Link to Item
-
Case, Laura E., Rabi Hanna, Donald P. Frush, Vidya Krishnamurthy, Stephanie DeArmey, Joanne Mackey, Anne Boney, et al. “Fractures in children with Pompe disease: a potential long-term complication.” Pediatr Radiol 37, no. 5 (May 2007): 437–45. https://doi.org/10.1007/s00247-007-0428-y.Full Text Link to Item
-
Weber, T. J., and D. T. Gold. “Update on male osteoporosis.” Advanced Studies in Medicine 6, no. 4 (April 1, 2006): 171–81.
-
Wang, Christina, Ronald Swerdloff, Mark Kipnes, Alvin M. Matsumoto, Adrian S. Dobs, Glenn Cunningham, Laurence Katznelson, et al. “New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.” J Clin Endocrinol Metab 89, no. 8 (August 2004): 3821–29. https://doi.org/10.1210/jc.2003-031866.Full Text Link to Item
-
Wang, Christina, Glenn Cunningham, Adrian Dobs, Ali Iranmanesh, Alvin M. Matsumoto, Peter J. Snyder, Thomas Weber, Nancy Berman, Laura Hull, and Ronald S. Swerdloff. “Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.” J Clin Endocrinol Metab 89, no. 5 (May 2004): 2085–98. https://doi.org/10.1210/jc.2003-032006.Full Text Link to Item
-
Weber, Thomas J., Shiguang Liu, Olafur S. Indridason, and L Darryl Quarles. “Serum FGF23 levels in normal and disordered phosphorus homeostasis.” J Bone Miner Res 18, no. 7 (July 2003): 1227–34. https://doi.org/10.1359/jbmr.2003.18.7.1227.Full Text Link to Item
-
Weber, T. J., and M. K. Drezner. “Effect of alendronate on bone mineral density in male idiopathic osteoporosis.” Metabolism 50, no. 8 (August 2001): 912–15. https://doi.org/10.1053/meta.2001.24925.Full Text Link to Item
-
Wang, C., R. S. Swerdloff, A. Iranmanesh, A. Dobs, P. J. Snyder, G. Cunningham, A. M. Matsumoto, T. Weber, and N. Berman. “Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.” Clin Endocrinol (Oxf) 54, no. 6 (June 2001): 739–50. https://doi.org/10.1046/j.1365-2265.2001.01271.x.Full Text Link to Item
-
Swerdloff, R. S., C. Wang, G. Cunningham, A. Dobs, A. Iranmanesh, A. M. Matsumoto, P. J. Snyder, T. Weber, J. Longstreth, and N. Berman. “Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.” J Clin Endocrinol Metab 85, no. 12 (December 2000): 4500–4510. https://doi.org/10.1210/jcem.85.12.7045.Full Text Link to Item
-
Wang, C., R. S. Swerdloff, A. Iranmanesh, A. Dobs, P. J. Snyder, G. Cunningham, A. M. Matsumoto, T. Weber, and N. Berman. “Erratum: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men (Journal of Clinical Endocrinology and Metabolism 85 (2839-2853)).” Journal of Clinical Endocrinology and Metabolism 85, no. 10 (November 22, 2000): 3525.
-
Wang, C., R. S. Swerdloff, A. Iranmanesh, A. Dobs, P. J. Snyder, G. Cunningham, A. M. Matsumoto, T. Weber, N. Berman, and N. Testosterone Gel Study Group. “Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.” J Clin Endocrinol Metab 85, no. 8 (August 2000): 2839–53. https://doi.org/10.1210/jcem.85.8.6747.Full Text Link to Item
-
Weber, T. J., and L. D. Quarles. “Preventing bone loss after renal transplantation with bisphosphonates: we can... but should we?” Kidney Int 57, no. 2 (February 2000): 735–37. https://doi.org/10.1046/j.1523-1755.2000.00900.x.Full Text Link to Item
-
Weber, T. J., J. B. Green, H. Chow, A. Spitz, and G. S. Wagner. “How bone density testing influenced osteoporosis treatment in a community hospital.” N C Med J 61, no. 6 (2000): 321–24.Link to Item
-
Harper, K. D., and T. J. Weber. “Secondary osteoporosis. Diagnostic considerations.” Endocrinol Metab Clin North Am 27, no. 2 (June 1998): 325–48. https://doi.org/10.1016/s0889-8529(05)70008-6.Full Text Link to Item
-
Wong, M., Y. Ikeda, X. Luo, K. M. Caron, T. J. Weber, A. Swain, B. P. Schimmer, and K. L. Parker. “Steroidogenic factor 1 plays multiple roles in endocrine development and function.” Recent Prog Horm Res 52 (1997): 167–82.Link to Item
-
Ikeda, Y., A. Swain, T. J. Weber, K. E. Hentges, E. Zanaria, E. Lalli, K. T. Tamai, et al. “Steroidogenic factor 1 and Dax-1 colocalize in multiple cell lineages: potential links in endocrine development.” Mol Endocrinol 10, no. 10 (October 1996): 1261–72. https://doi.org/10.1210/mend.10.10.9121493.Full Text Link to Item
-
-
Other Articles
-
Elfenbein, Dawn M., Thomas J. Weber, and Randall P. Scheri. “Tumor-induced osteomalacia masking primary hyperparathyroidism.” Surgery, December 2012. https://doi.org/10.1016/j.surg.2012.08.062.Full Text Link to Item
-
-
Conference Papers
-
De Beur, Suzanne Jan, Paul D. Miller, Thomas J. Weber, Munro Peacock, Karl L. Insogna, Rajiv Kumar, Frank Rauch, et al. “Burosumab Improved Serum Phosphorus, Osteomalacia, Mobility, and Fatigue in the 48-Week, Phase 2 Study in Adults with Tumor-induced Osteomalacia Syndrome.” In Journal of Bone and Mineral Research, 33:50–50. WILEY, 2018.Link to Item
-
De Beur, Suzanne Jan, Paul D. Miller, Thomas J. Weber, Munro Peacock, Mary D. Ruppe, Karl Insogna, Diana Luca, Christina Theodore-Oklota, Javier San Martin, and Thomas Carpenter. “Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS).” In Journal of Bone and Mineral Research, 32:S280–S280. WILEY, 2017.Link to Item
-
Weber, T. J., E. K. Sawyer, S. Moseley, T. OdrIjin, and P. S. Kishnani. “FRACTURE AND SURGICAL BURDEN IN PEDIATRIC AND ADULT PATIENTS WITH HYPOPHOSPHATASIA: RESULTS FROM PATIENT-REPORTED OUTCOME SURVEYS.” In Osteoporosis International, 26:S90–91. SPRINGER LONDON LTD, 2015.Link to Item
-
Hyland, Kristen Anne, and Thomas Joseph Weber. “Unrecognized Milk-Alkali Syndrome with Hypocalcemia Following Bisphosphonate Treatment.” In Endocrine Reviews, Vol. 35. ENDOCRINE SOC, 2014.Link to Item
-
Imel, Erik Allen, Xiaoping Zhang, Mary Denise Ruppe, Thomas Joseph Weber, Mark Klausner, Takahiro Ito, Maria Vergeire, et al. “The First Multi-Dose Trial of a Human Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) in Adults with X-Linked Hypophosphatemia (XLH).” In Endocrine Reviews, Vol. 35. ENDOCRINE SOC, 2014.Link to Item
-
Ruppe, Mary Denise, Xiaoping Zhang, Erik Allen Imel, Thomas Joseph Weber, Mark Klausner, Takahiro Ito, Maria Vergeire, et al. “Effect of Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) on Quality of Life in X-Linked Hypophosphatemia (XLH).” In Endocrine Reviews, Vol. 35. ENDOCRINE SOC, 2014.Link to Item
-
Zhang, Xiaoping, Erik Allen Imel, Mary Denise Ruppe, Thomas Joseph Weber, Mark Klausner, Takahiro Ito, Maria Vergeire, et al. “Pharmacokinetics (PK) and Pharmacodynamics (PD) Following Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) in Adults with X-Linked Hypophosphatemia (XLH).” In Endocrine Reviews, Vol. 35. ENDOCRINE SOC, 2014.Link to Item
-
Whyte⁎, M. P., C. R. Greenberg, P. Kishnani, K. Madson, A. Mhanni, T. J. Weber, K. Mack, et al. “Enzyme replacement therapy (ENB-0040) in hypophosphatasia improves functional outcome and decreases TNSALP substrates in adolescents and adults.” In Bone, 50:S39–S39. Elsevier BV, 2012. https://doi.org/10.1016/j.bone.2012.02.101.Full Text
-
Pham, A. N., S. K. Datta, T. J. Weber, L. C. Walter, and C. S. Colon-Emeric. “Cost-Effectiveness of Oral Bisphosphonates for Osteoporosis at Different Ages and Levels of Life Expectancy.” In Endocrine Reviews, Vol. 31. ENDOCRINE SOC, 2010.Link to Item
-
Padhi, D., A. Kivitz, T. J. Weber, K. Lyles, E. Lee, B. Cooke, H. Deng, and E. Posvar. “An Assessment of Serum Calcium and Bone Resorption Markers in Patients Transitioned from Alendronate to Denosumab.” In Journal of Bone and Mineral Research, 23:S473–S473. AMER SOC BONE & MINERAL RES, 2008.Link to Item
-
Shipp, K. M., E. Hegedus, C. F. Pieper, H. White, J. K. Richardson, T. J. Weber, and H. Hoenig. “Rehabilitation after Clinically-diagnosed Osteoporotic Vertebral Fracture: Results of a Pilot Study.” In Journal of Bone and Mineral Research, 23:S346–47. AMER SOC BONE & MINERAL RES, 2008.Link to Item
-
Parker, J. C., D. Kelling, and T. J. Weber. “Prevalence of hypovitaminosis D (vitamin D insufficiency and deficiency) in southern elderly osteoporotic patients.” In Journal of Bone and Mineral Research, 18:S408–S408. AMER SOC BONE & MINERAL RES, 2003.Link to Item
-
Weber, T. J., and M. K. Drezner. “Alendronate increases bone mineral density in male idiopathic osteoporosis.” In Journal of Bone and Mineral Research, 14:S278–S278. AMER SOC BONE & MINERAL RES, 1999.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.